IgAN
Advertisement
NephCure has announced the first IgA Nephropathy (IgAN) Awareness Day, happening September 26, 2024.
The FDA has granted full approval to sparsentan to slow kidney function decline in adults with primary IgA nephropathy.
Prevalence of IgA nephropathy (IgAN) and a summary of treatment patterns across Asian countries are lacking.
Urinary inflammatory biomarkers may be considered as alternative predictive biomarkers in patients with IgAN.
Researchers studied the LM pattern of glomerular injury and mesangial C3 staining in IgA nephropathy (IgAN).
Members of the Nephrology Times editorial board shared the nephrology research and news they’ve found most notable this ...
Results of Nefecon (budesonide) for IgA nephropathy set the stage for a glomerulonephritis renaissance.
Atrasentan showed a statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN).
Dr. Chee Kay Cheung discussed two presentations on IgA nephropathy findings from the SPARTAN and PROTECT studies.
The FDA has granted Breakthrough Therapy Designation to atacicept to treat IgA nephropathy (IgAN).
Researchers shared interim results from the ORIGIN study of atacicept in patients with IgA nephropathy.
Dr. Dana Rizk discussed her APPLAUSE-IgAN study findings on iptacopan versus placebo for IgA nephropathy.
Sparsentan demonstrated meaningful benefits for preservation of kidney function compared with irbesartan over 2 years.
The APPLAUSE-IgAN study evaluated iptacopan plus supportive care in patients with IgA nephropathy (IgAN).
The PROTECT trial evaluated sparsentan versus irbesartan for nephroprotection in IgA nephropathy (IgAN).
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.